Novel mechanistic insights into ectodomain shedding of EGFR Ligands Amphiregulin and TGF-α: impact on gastrointestinal cancers driven by secondary bile acids.
暂无分享,去创建一个
Xi Chen | M. Washington | N. Merchant | A. Lockhart | Y. Beesetty | Wooin Lee | Nagaraj Nagathihalli | Nagaraj S Nagathihalli | Yugandhar Beesetty | Nagaraj S. Nagathihalli
[1] P. Jänne,et al. The quest to overcome resistance to EGFR-targeted therapies in cancer , 2013, Nature Medicine.
[2] Masahira Hattori,et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome , 2013, Nature.
[3] J. Auwerx,et al. The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. , 2011, Journal of hepatology.
[4] C. Blobel,et al. A transforming Src mutant increases the bioavailability of EGFR ligands via stimulation of the cell-surface metalloproteinase ADAM17 , 2011, Oncogene.
[5] M. Washington,et al. Combined Blockade of Src Kinase and Epidermal Growth Factor Receptor with Gemcitabine Overcomes STAT3-Mediated Resistance of Inhibition of Pancreatic Tumor Growth , 2011, Clinical Cancer Research.
[6] S. Shak,et al. Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer , 2011, British Journal of Cancer.
[7] M. Washington,et al. Targeted Inhibition of Src Kinase Signaling Attenuates Pancreatic Tumorigenesis , 2010, Molecular Cancer Therapeutics.
[8] L. Sancey,et al. Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[9] Jie Hong,et al. Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma , 2009, Gut.
[10] H. Bernstein,et al. Bile acids as endogenous etiologic agents in gastrointestinal cancer. , 2009, World journal of gastroenterology.
[11] O. Sansom,et al. A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model. , 2009, Carcinogenesis.
[12] Armanda D. Tatsas,et al. Epithelial-Mesenchymal Transition Markers in Pancreatic Ductal Adenocarcinoma , 2009, Pancreas.
[13] H. Kung,et al. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530 , 2008, Oncogene.
[14] P. Johnston,et al. Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL. , 2008, Cancer research.
[15] H. Bernstein,et al. Field defects in progression to gastrointestinal tract cancers. , 2008, Cancer letters.
[16] B. LaFleur,et al. TACE/ADAM-17: A Component of the Epidermal Growth Factor Receptor Axis and a Promising Therapeutic Target in Colorectal Cancer , 2008, Clinical Cancer Research.
[17] O. Rath,et al. MAP kinase signalling pathways in cancer , 2007, Oncogene.
[18] M. Bissell,et al. Targeting TACE-dependent EGFR ligand shedding in breast cancer. , 2007, The Journal of clinical investigation.
[19] Nadarajah Vigneswaran,et al. Cigarette smoke condensate induces cytochromes P450 and aldo-keto reductases in oral cancer cells. , 2006, Toxicology letters.
[20] David C. Lee,et al. Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. , 2006, Cancer research.
[21] G. Mills,et al. Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[22] N. Nagaraj,et al. Hypoxia inhibits TRAIL-induced tumor cell apoptosis: Involvement of lysosomal cathepsins , 2006, Apoptosis.
[23] Yusuke Nakamura,et al. Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. , 2005, Cancer research.
[24] Ho-Yyoung Lee,et al. Resistance to epidermal growth factor receptor-targeted therapy. , 2005, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[25] J. Morrow,et al. Ligand-dependent activation of the epidermal growth factor receptor by secondary bile acids in polarizing colon cancer cells. , 2005, Surgery.
[26] Jing-Yuan Fang,et al. The MAPK signalling pathways and colorectal cancer. , 2005, The Lancet. Oncology.
[27] J. Baselga,et al. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] C. Blobel,et al. ADAMs: key components in EGFR signalling and development , 2005, Nature Reviews Molecular Cell Biology.
[29] D. Schuppan,et al. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. , 2004, Journal of hepatology.
[30] G. Jenkins,et al. The bile acid deoxycholic acid (DCA) at neutral pH activates NF-kappaB and induces IL-8 expression in oesophageal cells in vitro. , 2003, Carcinogenesis.
[31] R. Coffey,et al. Transforming Growth Factor-Alpha (TGF-alpha) Levels in Human Proximal Gastrointestinal Epithelium (Effect of Mucosal Injury and Acid Inhibition) , 1997, Digestive Diseases and Sciences.
[32] Stefan Hart,et al. TACE cleavage of proamphiregulin regulates GPCR‐induced proliferation and motility of cancer cells , 2003, The EMBO journal.
[33] David C. Lee,et al. TACE/ADAM17 Processing of EGFR Ligands Indicates a Role as a Physiological Convertase , 2003, Annals of the New York Academy of Sciences.
[34] Masataka Harada,et al. A G Protein-coupled Receptor Responsive to Bile Acids* , 2003, The Journal of Biological Chemistry.
[35] Robert J Coffey,et al. EGF receptor ligands. , 2003, Experimental cell research.
[36] D. Wakelin,et al. Upregulation of the oncogene c-myc in Barrett’s adenocarcinoma: induction of c-myc by acidified bile acid in vitro , 2003, Gut.
[37] T. Yeatman,et al. Increased Src activity disrupts cadherin/catenin-mediated homotypic adhesion in human colon cancer and transformed rodent cells. , 2002, Cancer research.
[38] G. Gores,et al. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. , 2002, Gastroenterology.
[39] Heike Allgayer,et al. Activation of Src kinase in primary colorectal carcinoma , 2002, Cancer.
[40] M. Mareel,et al. The role of bile acids in carcinogenesis. , 2001, Mutation research.
[41] R. Nicholson,et al. EGFR and cancer prognosis. , 2001, European journal of cancer.
[42] E. Rozengurt,et al. EGF receptor function is required in late G(1) for cell cycle progression induced by bombesin and bradykinin. , 2001, American journal of physiology. Cell physiology.
[43] Jesse D. Martinez,et al. Activation and role of mitogen-activated protein kinases in deoxycholic acid-induced apoptosis. , 2001, Carcinogenesis.
[44] G. Carpenter. Employment of the Epidermal Growth Factor Receptor in Growth Factor–Independent Signaling Pathways , 1999, The Journal of cell biology.
[45] F. McCormick,et al. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. , 1999, Nature.
[46] J. Grandis,et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. , 1998, The Journal of clinical investigation.
[47] A. Ullrich,et al. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors , 1996, Nature.
[48] G. Paumgartner,et al. Increased serum deoxycholic acid levels in men with colorectal adenomas. , 1993, Gastroenterology.
[49] N. Normanno,et al. Differential immunohistochemical detection of amphiregulin and cripto in human normal colon and colorectal tumors. , 1992, Cancer research.
[50] R. Coffey,et al. Amphiregulin messenger RNA is elevated in psoriatic epidermis and gastrointestinal carcinomas. , 1992, Cancer research.